Biocon Biologics and Yoshindo Inc. launch Ustekinumab Biosimilar in Japan
Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA).
In April 2024, the Company entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan upon regulatory approval. Biocon Biologics' biosimilar Ustekinumab BS Subcutaneous Injection [YD] was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in December 2024.
Biocon Biologics has already launched Ustekinumab in the United States and Europe in February 2025 to help patients manage their chronic conditions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
3 hours ago
- Economic Times
Stocks to buy or sell today: Biocon, Voltas among 7 trading ideas for 15 July 2025
Indian market is expected to consolidate, mirroring mixed global signals. Nifty futures closed negatively, while India VIX saw an increase. Indian market is expected to consolidate, mirroring mixed global signals, with Nifty futures closing negatively. Option data indicates a trading range between 24,600 and 25,600. Experts recommend buying Biocon, LIC Housing Finance, Marico, Prestige Estates, Ambuja Cements, and Voltas, while suggesting selling Tata Motors for short-term gains. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads We have collated stocks from various experts for traders who have a short-term trading horizon: Expert: Ajit Mishra – SVP, Research, Religare Broking Ltd told ETBureau Expert: Sharan Lillaney, Independent SEBI Research Analyst Tired of too many ads? Remove Ads The Indian market is likely to consolidate on Tuesday, tracking mixed global Nifty future closed negatively with losses of 0.20% at 25,173 levels on Monday. India VIX was up 1.3% to close at 11.98 in the previous the options front, the maximum Call OI is at 25,500 and then at 25,300 strikes, while the maximum Put OI is at 25,000 and then at 25,100 writing is seen at 25,100 and then at 25,200 strikes, while Put writing is seen at 25,100 and then at 25,000 strikes.'Options data suggests a broader trading range in between 24,600 to 25,600 zones while an immediate range between 24,800 to 25,300 levels,' Chandan Taparia, Analyst-Derivatives at Motilal Oswal Financial Services Limited , said.'Nifty formed a bearish candle on the daily frame on Monday and has begun to slope downward as its making lower top - lower bottom structure indicating some selling pressure is intact at bounce,' he added.'Now till the Nifty index holds below 25,150 zones, weakness could be seen towards 25,000 then 24,800 zones while hurdles are shifting lower at 25,222 then 25,350 zones,' recommended Target Rs 398| Stop Loss Rs 368Buy| Target Rs 628| Stop Loss Rs 694Buy| Target Rs 755| Stop Loss Rs 714Sell| Target Rs 642| Stop Loss Rs 692Buy| Target Rs 1776| Stop Loss Rs 1676Buy| Target Rs 605| Stop Loss Rs 575Buy| Target Rs 1401| Stop Loss Rs 1351
Mint
6 days ago
- Mint
From Laurus Labs, Lupin to Biocon— Pharma stocks rise up to 3% despite Trump's 200% tariff threat
Pharma stocks exhibited remarkable resilience in the morning trade on Wednesday, July 9, despite US President Donald Trump's threat of a very high tariff of up to 200 per cent. Several pharma stocks, including Laurus Labs, Lupin, Biocon, Cipla and Divi's Labs, rose up to 3 per cent in the morning session, pushing their sectoral index, Nifty Pharma, higher by about half a per cent in a weak market. The Nifty Pharma index was up 0.30 per cent at 22,231, around 9:50 AM, with 14 out of the total 20 stocks in the green. Equity benchmark Nifty 50 was 0.13 per cent down at 25,489 at that time. As Mint reported earlier, Trump has warned that pharmaceuticals could face an even steeper tariff, though he suggested the move would not be immediate. 'They're going to be tariffed at a very, very high rate, like 200 per cent,' Trump said, adding that the measure would be announced soon and take effect after at least a year. Steeper tariffs on pharmaceutical imports to the US could be a significant negative for Indian pharma firms, as the US is India's largest overseas market for pharmaceuticals. (This is a developing story. Please check back for fresh updates.)
Hans India
08-07-2025
- Hans India
No malafide intention by CM
Bengaluru: Health MinisterDinesh Gundu Rao on Monday said Chief Minister Siddaramaiah's statement linking Covid vaccine with the spate of heart attacks was not with any malafide intention. The CM had suggested that the heart attack deaths in Hassan district may be linked to the vaccination drive. He also claimed that the vaccines were 'hastily' approved. His statement drew sharp criticism from the BJP and the likes of Biocon founder Kiran Mazumdar-Shaw. "The CM's intention was good but some people mistook it. He wanted to know about the side effects of Covid and its vaccine," Rao told reporters here. In a post on 'X', the CM had said, "It cannot be denied that the hasty approval and distribution of the Covid vaccine to the public could also be a reason for these deaths, as several studies worldwide have recently indicated that COVID vaccines could be a cause for the increasing number of heart attacks. Before BJP criticize us on this matter, they should ask their conscience." An expert committee tasked with investigating the recent cases of heart attack deaths in Karnataka said there is no association between premature cardiovascular disease in a patient and a prior history of Covid-19 infection or Covid vaccination. On the contrary, a report submitted by the panel said Covid-19 vaccination has been shown to be protective against cardiac events in the long term.
